Categories
Cardiovascular
Diagnostics
Endocrinology
Health Insurance
Medical Devices
Mental Health
Nutrition
Oncology
Public Health
Sexual Health
Popular Articles

HIV/AIDS, Gay Rights Advocate McFarlane Dies
Rodger McFarlane, a leader in gay rights and HIV/AIDS advocacy efforts, died on Friday in New Mexico at age 54, the New York Times reports. According to McFarlane"s brother, John, he committed suicide. In a letter, McFarlane wrote that he did not want to become further debilitated by heart and back problems, the Times reports. McFarlane was the director of the Gay Men"s Health Crisis from 1982 to 1985, and served as the executive director of Broadway Cares/Equity Fights AIDS from 1989 to 1994. He also served as president of the HIV/AIDS and housing organization Bailey House, and from 2004 to 2008 was the executive director of the Gill Foundation in Denver. "AIDS pointed to the inequitable status of gays," McFarlane said in the Times in 1983, adding, "We were forced to take care of ourselves because we learned that if you have certain diseases, certain lifestyles, you can"t expect the same services as other parts of society" (Hevesi, New York Times, 5/19). Tim Sweeney, president of the Gill Foundation, said in a statement, "We will eternally be in his debt as a result of his many, lasting contributions" (AP/Google.com, 5/18).
generic viagra online
Proportion Of Fatal Crashes Increases
An emergency rule intended to reduce the number of deaths and injuries associated with Hawaiian air tours was followed by a 47 percent reduction in sightseeing crashes, according to a new study by researchers from the Johns Hopkins Bloomberg School of Public Health"s Center for Injury Research and Policy.
News of the day
Evaluating The ADHD Medication VYVANSE CII Demonstrated No Change In Pharmacokinetic Profile Of VYVANSE When Coadministered With Prilosec OTC 40 Mg
Shire plc (LSE: SHP, NASDAQ: SHPGY), the global specialty biopharmaceutical company, announced results of a study showing that coadministration of the ADHD medication VYVANSE® (lisdexamfetamine dimesylate) CII with the proton pump inhibitor (PPI) Prilosec OTC® 40 mg (20 mg X 2), did not alter the median time it took for maximum plasma concentration of d-amphetamine to be reached in the subjects evaluated. In the same study, coadministration of Prilosec OTC with ADDERALL XR resulted in a nearly 45 percent reduction in the median time to reach maximum plasma concentrations of amphetamine, the active medication. Other pharmacokinetic parameters (maximum plasma concentration and area under curve) of active medication were not altered for either VYVANSE or ADDERALL XR when coadministered with Prilosec OTC. This study, which is the first to evaluate the pharmacokinetics of VYVANSE and ADDERALL XR taken alone and with Prilosec OTC 40 mg, was recently presented at the International Congress on Clinical Pharmacy, co-sponsored by the American College of Clinical Pharmacy (ACCP), in Orlando, FL.
Health Insurance

Cougar Biotechnology Announces Successful Completion Of Johnson & Johnson's Initial Tender Offer And Commencement Of Subsequent Offering Period

Cougar Biotechnology, Inc. (NASDAQ: CGRB) announced today that the initial offering period of Johnson & Johnson"s (NYSE: JNJ) tender offer for all the outstanding shares of Cougar common stock expired at midnight (Eastern time) on July 2, 2009. The offer was conducted through a wholly-owned subsidiary of Johnson & Johnson named Kite Merger Sub, Inc. The depositary for the tender offer has advised Cougar that, as of the expiration of the initial offering period, a total of approximately 17,742,030 shares of Cougar common stock were validly tendered and not withdrawn, representing approximately 84.4% of Cougar common stock that is outstanding. All shares that were validly tendered and not properly withdrawn during the offering period have been accepted for payment. In addition, the depositary has received commitments to tender approximately 2,001,065 additional shares under the guaranteed delivery procedures described in the offer. Johnson & Johnson has advised Cougar that it is commencing through Kite Merger Sub, Inc., a subsequent offering period of its tender offer to acquire all remaining outstanding shares of Cougar common stock. This subsequent tender offering period will expire at 5:00 p.m. (Eastern time) on Thursday July 9, 2009, unless extended. Any shares validly tendered during this subsequent offering period will be accepted immediately for payment, and tendering stockholders will thereafter promptly be paid $43.00 in cash for each share of Cougar common stock tendered, without interest and less any required withholding taxes. This is the same amount per share that was offered and paid in the initial offering period. Shares tendered during this subsequent offering period cannot be delivered by the guaranteed deliver procedure and may not be withdrawn. In addition, shares validly tendered during the initial offering period may not be withdrawn during the subsequent offering period. Following the expiration of the subsequent offering period, Johnson & Johnson has advised Cougar that it intends to acquire any remaining shares of Cougar common stock through what is known as a "short-form" merger," that is, without a vote or meeting of the remaining stockholders of Cougar. Cougar Biotechnology, Inc.


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):

© Copyright 2009